Onkológia 6/2008

GASTROINTESTINAL STROMAL TUMOR – A COMPREHENSIVE VIEW OF DIAGNOSTICS AND TREATMENT

Gastrointestinal stromal tumors, while rare,are the most common mesenchymal tumors of the gastrointestinal tract. 80 % tumors of GIST carry oncogenic mutation in the KIT, 8% in the PDGF and about 20 – 25 % carry no mutation wild typ. By the introduction of imatinib to the treatment, median survival has been extended to 3 – 5 years.The standard dose of imatinib is 400 mg/day for all patients except those, which known exon 9 mutation.The recommended dose for them is 800 mg/day.The favorable response rates with imatinib in the treatment of advanced GIST have generated great interest in its use in the adjuvant setting. For imatinib-resistant disease is recommended sunitinib.

Keywords: gastrointestinal stromal tumor, imatinib mesylate, sunitinib